LCINQ — Lannett Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.32m
- $582.17m
- $340.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -61.94% | ||
Financial Summary
| Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 684.56 | 655.41 | 545.74 | 478.78 | 340.58 | 299.94 | 305.46 | -11.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +4.21 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
Directors
- Patrick Lepore NEC (66)
- Timothy Crew CEO (60)
- John Kozlowski CFO (49)
- John Abt COO (56)
- Maureen Cavanaugh SVP (62)
- Samuel Israel GCN (60)
- Jeffrey Farber DRC (61)
- John Chapman IND (67)
- David Drabik IND (53)
- Melissa Rewolinski IND (52)
- Last Annual
- June 30th, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- December 3rd, 1991
- Public Since
- July 21st, 2008
- No. of Shareholders
- 202
- No. of Employees
- 564
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 10,780,187
- Address
- 1150 Northbrook Drive, Suite 155, TREVOSE, 19053
- Web
- https://www.lannett.com/
- Phone
- +1 2153339000
- Auditors
- Grant Thornton LLP
Upcoming Events for LCINQ
Q1 2024 Lannett Company Inc Earnings Release
Similar to LCINQ
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Soul Biotechnology
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
What is the Lannett share price?
As of Today at 01:12 UTC, shares in Lannett are trading at $0.03. This share price information is delayed by 15 minutes.
How has the Lannett share price performed this year?
Shares in Lannett last closed at $0.03 and the price had moved by -98.77% over the past 365 days. In terms of relative price strength the Lannett share price has underperformed the S&P500 Index by -98.91% over the past year.
What are the analyst and broker recommendations for Lannett?
The overall consensus recommendation for Lannett is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lannett dividend yield?
Lannett does not currently pay a dividend.
Does Lannett pay a dividend?
Lannett does not currently pay a dividend.
When does Lannett next pay dividends?
Lannett does not currently pay a dividend.
How do I buy Lannett shares?
To buy shares in Lannett you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lannett?
As of the previous close price of $0.03, shares in Lannett had a market capitalisation of $0.32m.
Where are Lannett shares listed?
Here are the trading details for Lannett:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: LCINQ
What kind of share is Lannett?
Based on an overall assessment of its quality, value and momentum Lannett is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lannett share price forecast for 2023?
The analyst consensus target price for shares in Lannett is $4.00. That is 13390.73% above the last closing price of $0.03.
Analysts covering Lannett currently have a consensus Earnings Per Share (EPS) forecast of -$6.20 for the next financial year.
Find out moreWhat is the trend in the Lannett share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lannett. Over the past six months, its share price has underperformed the S&P500 Index by -98.98%.
As of the last closing price of $0.03, shares in Lannett were trading -98.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lannett PE Ratio?
The Lannett PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lannett?
Lannett's management team is headed by:
- Patrick Lepore - NEC
- Timothy Crew - CEO
- John Kozlowski - CFO
- John Abt - COO
- Maureen Cavanaugh - SVP
- Samuel Israel - GCN
- Jeffrey Farber - DRC
- John Chapman - IND
- David Drabik - IND
- Melissa Rewolinski - IND